Pregled bibliografske jedinice broj: 1158546
Salvage radiotherapy of prostate cancer: retrospective analysis of 10 years' experience in the Department of Oncology and Radiotherapy,University Hospital of Split
Salvage radiotherapy of prostate cancer: retrospective analysis of 10 years' experience in the Department of Oncology and Radiotherapy,University Hospital of Split, 2018., diplomski rad, diplomski, Medicinski fakultet, Split
CROSBI ID: 1158546 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Salvage radiotherapy of prostate cancer: retrospective analysis of 10 years' experience in the Department of Oncology and Radiotherapy,University Hospital of Split
Autori
Radošević Sebastian
Vrsta, podvrsta i kategorija rada
Ocjenski radovi, diplomski rad, diplomski
Fakultet
Medicinski fakultet
Mjesto
Split
Datum
11.07
Godina
2018
Stranica
56
Mentor
Omrčen Tomislav
Ključne riječi
Salvage radiotherapy, prostate cancer
Sažetak
Objectives: We evaluated the clinical outcomes of patients treated with salvage radiotherapy (SRT) after biochemical relapse regarding the biochemical control after surgery, overall survival (OS) and metastatic-free survival (MFS). Materials and Methods: A retrospective cohort study (from 2006 until 2015) using the data collected from patient charts in the Department of Oncology and Radiotherapy in Split with missing data requested from Zadar, Šibenik and Dubrovnik. A total of 124 patients treated with salvage radiotherapy after developing biochemical relapse following radical prostatectomy (RP) were included into this study. Results: The median follow-up from salvage radiotherapy to the 1.2.18 was 58 months with 68 years being the median age of the patients. Therapy was started after a median of 5.5 months. Out of the 124 patients, 68 started SRT with a PSA level below 0.7 ng/ml. 80 patients respond-ed to the therapy with drop in PSA of more than 90%. Progression after SRT was observed in 33 patients and 4 patients developed metastases. This leads to a median biochemical relapse-free survival (BRFS) of 26 months, OS of 53 months, an MFS of 52.5 months. The 5-year overall survival of the patients included is 91.7% (95%CI= 85.71 to 97.90) ; the 5-year biochemical relapse-free survival was 85.51% (95%CI = 76.68 to 94.33) and the 5-year metastases-free survival was 91.09% (95%CI = 85.00 to 97.35). A relationship was shown between lympho-vascular invasion and MFS (P=0.015) and OS (P=0.005). Perineural invasion (P=0.034) and the TNM stage (P=0.047) show a relation to OS. Other relationships were not observed. Conclusion: Patients treated with SRT show a good biochemical response after the therapy. If the surrounding tissues were not involved and the initial TNM stage is low, the outcomes im-prove leading to a better MFS and OS.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti